To further demonstrate that MEKi growth inhibition effect was dependent on CD15/FUT4 expression levels, we used public data from three selective MEK inhibitors, BAY 86–9766, Selumetinib and Pimasertib in a panel of six CRC cell lines. The gene discussed is MAP2K7; the disease is colorectal carcinoma.